FOR IMMEDIATE RELEASE, Illinois – United States – October 14, 2013 (PR Carbon):Reportstack has announced a new market report on Tuberculosis Partnering 2007-2013 which provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in tuberculosis partnering deals Top tuberculosis deals by value, Deals listed by company A-Z, industry sector, stage of development, technology type. The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This data driven report contains over 130 links to online copies of actual tuberculosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The report provide an orientation of tuberculosis partnering trends, an introduction to the report, overview of the trends in tuberculosis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends, provides an overview of the leading tuberculosis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active of all bio pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract, a comprehensive directory of tuberculosis partnering deals signed and announced since 2007. The Report scope: Tuberculosis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to tuberculosis trends and structure of deals entered into by leading companies worldwide.
This data driven report includes: Trends in tuberculosis dealmaking in the biopharma industry since 2007, Access to summary headline, upfront, milestone and royalty data, The leading tuberculosis deals by value since 2007. The Reasons to Buy: Tuberculosis Partnering 2007-2013 provides the reader with the following key benefits: In-depth understanding of tuberculosis deal trends since 2007, Access to summary headline, upfront, milestone and royalty data, Comprehensive access to over 130 actual tuberculosis deals entered into by the world’s biopharma companies since 2007, Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals, Undertake due diligence to assess suitability of your proposed deal terms for partner companies. To view the table of contents and know more details please visit Tuberculosis Partnering 2007-2013 report.